The U.S.-Cuba relationship for life sciences collaborations has great possibilities but also the uncertainty that life sciences leaders have said discourages investment and slows innovation.
President Obama’s efforts to thaw relations between the U.S. and Cuba have special resonance for me and others who grew up during the 1962 Cuban Missile Crisis that led to a U.S. economic embargo that generally bans the import and export of goods with Cuba.
Obama visited Cuba in March and has lifted some travel and trade restrictions.
Cuba has over the years developed its own life sciences industry, which has
developed drugs and vaccines that are unobtainable in the U.S., piqued the
interest of U.S. companies and created medical tourism in Cuba for terminally
U.S. citizens who, under U.S. travel restrictions, have gone there for
treatment by way of Canada or Peru.
But the embargo remains in place and, according to congressional insiders, is likely to remain so as long as Republicans control either the House or Senate. This leaves U.S. life sciences companies wishing to obtain approval to test and ultimately market drugs developed in Cuba in the U.S. one option: obtaining a license from the U.S. Treasury, which can take a while. This is the reason for the uncertainty that life sciences companies are battling.
I wrote a Special Report for Bloomberg BNA that describes the current situation, the efforts of some U.S. companies and nonprofits to obtain licenses, and some of the drugs and vaccines for which they want the licenses. It also lists an organization’s recommendations of things a U.S. president can do now to improve the situation. You can find the report here.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)